Evogene
EVGN
45 hedge funds and large institutions have $42M invested in Evogene in 2021 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 8 closing their positions.
220% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 5
150% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 8
36% more funds holding
Funds holding: 33 → 45 (+12)
0.4% less ownership
Funds ownership: 2.69% → 2.29% (-0.4%)
6% less capital invested
Capital invested by funds: $45M → $42M (-$2.92M)
26% less call options, than puts
Call options by funds: $1.13M | Put options by funds: $1.53M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.22M |
| 2 |
Millennium Management
New York
|
+$1.81M |
| 3 |
SM
Senvest Management
New York
|
+$1.66M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$1.25M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$945K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$13M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.55M |
| 3 |
Jane Street
New York
|
-$871K |
| 4 |
VF
Virtu Financial
New York
|
-$249K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$196K |
EVGN Hedge Fund Activity: Q1 2021 in Review
45 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q1 2021, worth a combined $42M — down 6.5% from $45M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new EVGN positions and 8 closed out — a net gain of 12 holders — while 16 added to existing stakes and 5 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $3.22M. The largest seller was Waddell & Reed Financial, exiting entirely with an estimated $13M sold.
- 45 institutional investors held Evogene (EVGN) as of Q1 2021, up from 33 in Q4 2020.
- Funds reported $42M of Evogene stock for Q1 2021, down 6.5% quarter-over-quarter.
- 20 funds opened new Evogene positions in Q1 2021 and 8 closed out, a net change of +12 holders.
- The largest Evogene buyer in Q1 2021 was Morgan Stanley, an estimated $3.22M added.
- The largest Evogene seller in Q1 2021 was Waddell & Reed Financial, an estimated $13M sold.
Based on aggregated 13F filings for Q1 2021.